Disruptive research to improve brain
tumour outcomes
tumour outcomes
Slide 1
Slide 2
Risk free solutions for all brain
tumour patients
tumour patients
Slide 3
Blockchain technology for clinical information management
Revolutionizing Brain Cancer Diagnosis and Treatment
Focus
Disruptive research in minimally invasive brain cancer diagnostics and therapeutics
Science
Single Cell multinomic approaches to answer the most demanding questions in neuro-oncology research
Technology
Blockchain based auditable distributed ledgers to collect and manage all clinical information
Products
Clinician lead products to address specific needs in current care pathway
Artificial Intelligence
Proprietary AI/ML algorithms trained on large databases for near perfect precision
Alliances
Geographically agnostic cloud based models allowing worldwide access and infinite scalability
Our Science
Introducing Liquid Biopsy, a minimally invasive diagnostic tool for brain tumours using a few drops of blood
Changing The Paradigm
Partners
Partnerships
In addition to our assosiation with the largest hospital chains in India, Exsegen is also a member of the Global Brain Liquid Biposy Consortium which is at the forefront of the global effort in standardizing the use of liquid biopsy in brain tumours.
Ongoing Clinical Trials
Exsegen is conducting clinical trials to diagnose brain lesions with a specificity and sensitivity approaching a traditional biopsy in any patient having a radiological lesion that may represent a brain tumour. Further details on our CTRI approved clinical trials can be accessed using the link below
Our Products
Exsegen’s product pipeline embraces the transformational advantages of Liquid Biopsy and deep tech platforms. We are in the process of developing new products to improve brain tumour patient outcomes.
Elsy, Our Clinical Management Solution
ELSY represents a technology solution that has the potential to revolutionise the way clinical trials are conducted. ELSY is designed to increase transparency and accountability in the trial process, from study design and protocol development to data collection and analysis. ELSY can potentially reduce study costs by eliminating manual processes, reducing errors and delays, and improving overall efficiency.
Meet The Team
Dr. Amitava
Ray
Founder & CEO
Surya
Madiraju
Co-Founder & Director
Kiran
Prathapa
CTO
Vikas
Pawar
COO
Moona
Chauhan
VP, Sales & Marketing
Yashoda
Ghanekar, PhD
VP, Science
Subhashini
Sadasivam, PhD
VP, Science
Pallavi
Goel, PhD
Bio-Tech Specialist
Vijay
Laxmi Roy
Research Analyst
Vijay
Sreegiriraju
VP, Technology
Advisors
Amit
Sircar
Goutam
Bhattacharyya, PhD
Jyoti
Sagar
Partha
Mazumdar, PhD
Indrajeet
Kaur, PhD
Publications & Posters
Our technical publications are a critical component of our strategy for staying at the forefront of thought leadership in the Brain cancer research. By sharing our research findings and technical expertise with the broader scientific community, we want to continue to innovate and grow knowledge in the years to come.
Careers
We appreciate your interest in joining our growing team. Please send your resume to hr@exsegen.com